Euroimmun, a Revvity company, and Xpedite Diagnostics have partnered to offer DNA extraction protocols for point-of-care diagnostics.

Alveo Technologies said Wednesday that it has struck 19 agreements for the distribution of its point-of-care molecular diagnostic products throughout Europe, Africa, and the Middle East.a

Geneoscopy and Adiso Therapeutics announced on Tuesday a strategic collaboration that will involve the use of Geneoscopy's stool-based transcriptome platform to assess patient response to Adiso's experimental treatment for inflammatory bowel disease (IBD).

Siemens Healthineers said Monday that it has secured a three-year, $5.5 million contract with the National Institute of Allergy and Infectious Diseases to develop a next-generation sequencing-based test to guide antimicrobial treatments in sepsis patients.

Biotech company AnchorDx has entered into a long-term partnership with molecular diagnostics firm DiaCarta to develop and commercialize cancer diagnostic products for the global market.

Hologic reported after the close of the market Thursday that its non-COVID fiscal fourth quarter organic revenues grew 17 percent compared to one year earlier on a constant currency basis with double-digit organic growth across all its divisions.

DiaSorin said on Friday that its third quarter revenues fell 17 percent year over year as COVID-19 testing revenues continued an expected decline and losses in non-COVID molecular diagnostics and licensing businesses further offset gains in the company's immunodiagnostics business.

Abbott announced on Thursday that its molecular test for human papillomavirus has received regulatory approval from the US Food and Drug Administration.

Abbott's RealTime IDH1 Assay has received approval from the US Food and Drug Administration as a companion diagnostic for Servier Pharmaceuticals' Tibsovo (ivosidenib) in patients with relapsed or refractory myelodysplastic syndrome, the FDA announced on Tuesday.

Roswell Park Cancer Center said this week that Agilent Technologies has licensed its blood cancer assay, PanHeme.